CIPLA vs MANKIND: Stock Comparison
Head-to-head financial and trading comparison between Cipla Limited (CIPLA) and Mankind Pharma Limited (MANKIND) in the Pharmaceuticals & Healthcare sector.
CIPLA
NSE: CIPLAMANKIND
NSE: MANKINDKey Metrics Comparison Table
| Metric | CIPLA | MANKIND | Edge / Winner |
|---|---|---|---|
| Current Market Price (CMP) | ₹1,344.00 | ₹2,535.00 | — |
| 1-Year Price Return | +9.31% | +21.93% | MANKIND (12.62% higher) |
| 52-Week High | ₹1,477.00 | ₹2,617.90 | — |
| 52-Week Low | ₹1,211.10 | ₹2,077.40 | — |
| 30-Day Annualized Volatility | 15.13% | 30.07% | CIPLA (Steadier) |
| 30-Day Average Daily Volume | 912,248 | 469,517 | CIPLA (Higher Liquidity) |
| Statutory Cost to Trade ₹1 Lakh | ₹118.50 | ₹118.50 | Identical statutory tariff |
Frequently Asked Questions
Between CIPLA and MANKIND, which stock gave better returns over the last year?
MANKIND has outperformed CIPLA over the past 12 months with a gain of 21.93% compared to 9.31%.
Which stock is less volatile: CIPLA or MANKIND?
CIPLA demonstrated lower price volatility (15.13% annualized) compared to MANKIND (30.07%). Lower volatility generally indicates steadier price action during market downturns.
What is the statutory cost to buy ₹1,00,000 of CIPLA vs MANKIND?
Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).
Are CIPLA and MANKIND direct sector competitors?
Yes, both companies operate within the Pharmaceuticals & Healthcare sector in India and are actively tracked as sector peers by institutional and retail market participants.